Is faster always better? What is the implication of a shorter time to imaging with tetrofosmin compared to sestamibi?-Reference-Cited by-同舟云学术

Is faster always better? What is the implication of a shorter time to imaging with tetrofosmin compared to sestamibi?

Published:2020-05-13 Issue:6 Volume:28 Page:2629-2632
ISSN:1071-3581
Container-title:Journal of Nuclear Cardiology
language:en
Short-container-title:J. Nucl. Cardiol.

Author:

Laipply Kelly,Gerson Myron

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Radiology, Nuclear Medicine and imaging

Link

https://link.springer.com/content/pdf/10.1007/s12350-020-02143-y.pdf

Reference9 articles.

1. Beller GA, Watson DD. Physiological basis of myocardial perfusion imaging with the technetium99m agents. Semin Nucl Med 1991;12:173-81.

2. Sogbein OO, Pelletier-Galarneau M, Schindler TH, Wei L, Wells RG, Ruddy TD. New SPECT and PET radiopharmaceuticals for imaging cardiovascular disease. Biomed Res Int 2014. https://doi.org/10.1155/2014/942960.

3. Wackers FJ, Berman DS, Maddahi J, Watson DD, Beller GA, Strauss HW, et al. Technetium-99m hexakis 2-methoxyisobutyl isonitrile: Human biodistribution, dosimetry, safety, and preliminary comparison to thallium-201 for myocardial perfusion imaging. J Nucl Med 1989;30:301-11.

4. Munch G, Neverve J, Matsunari I, Schroter G, Schwaiger M. Myocardial technetium-99m-tetrofosmin and technetium-99m-sestamibi kinetics in normal subjects and patients with coronary artery disease. J Nucl Med 1997;38:428-32.

5. Dorbala S, Ananthasubramaniam K, Armstrong IS, Chareonthaitawee P, DePuey EG, Einstein AJ, et al. Single photon emission computed tomography (SPECT) Myocardial Perfusion Imaging Guidelines: Instrumentation, acquisition, processing, and interpretation. J Nucl Cardiol 2018;25:1784-846.